1. Clinical & Scientific Overview
Fosfomycin Trometamol (TIP-MED-000154, Reference Code [8.26]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Phosphonic Acid Epoxide Cell-Wall (MurA) Synthesis Inhibitor — Single-Dose Oral UTI Sachet (Schedule H | ICMR Access/Watch).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.26], p. 105): Monurol (Modi Mundipharma/Zambon), Fosfocin (Cipla), Crifos, Fosirol (Sun) — Strengths & Dosage Forms: Oral Granules Sachet: 3 g Fosfomycin (equivalent to 5.631 g Fosfomycin Trometamol)
Oral Granules Sachet: 3 g Fosfomycin (equivalent to 5.631 g Fosfomycin Trometamol)
3. Mechanism of Action & Pharmacodynamics
Phosphonic Acid Epoxide Cell-Wall (MurA) Synthesis Inhibitor — Single-Dose Oral UTI Sachet (Schedule H | ICMR Access/Watch) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Phosphonic Acid Epoxide Cell-Wall (MurA) Synthesis Inhibitor — Single-Dose Oral UTI Sachet (Schedule H | ICMR Access/Watch) for Acute uncomplicated lower urinary tract infection (acute cystitis) in women caused by Escherichia coli (including many ESBL-producing E. coli strains!) or Enterococcus faecalis; peri-procedural prophylaxis for transrectal prostate biopsy.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute uncomplicated lower urinary tract infection (acute cystitis) in women caused by Escherichia coli (including many ESBL-producing E
- coli strains!) or Enterococcus faecalis
- peri-procedural prophylaxis for transrectal prostate biopsy
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Uncomplicated Acute Cystitis (Women): ONE single 3 g sachet PO as a single one-time dose! (In complicated lower UTI, specialists occasionally prescribe 3 g every 48–72 hours for 3 doses [Days 1, 3, & 5]). Does NOT achieve tissue levels for pyelonephritis!
Administration & Meal Timing: MANDATORY BEDTIME ADMINISTRATION RULE: Dissolve the 3 g sachet in half a glass (100–120 mL) of cool water (NEVER hot water!), stir, and drink immediately on an empty stomach (2–3 hours after dinner) AT BEDTIME AFTER EMPTYING THE BLADDER completely! | At Bedtime IMMEDIATELY AFTER Urinating (Single Dose)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted 90% unchanged in urine; avoid if CrCl <10 mL/min. Hepatic: Safe (no hepatic metabolism); safe in pregnancy (Category B) for lower UTI!
Renal: Excreted 90% unchanged in urine; avoid if CrCl <10 mL/min. Hepatic: Safe (no hepatic metabolism); safe in pregnancy (Category B) for lower UTI!
Renal: Excreted 90% unchanged in urine; avoid if CrCl <10 mL/min. Hepatic: Safe (no hepatic metabolism); safe in pregnancy (Category B) for lower UTI!
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in severe renal failure (CrCl <10 mL/min), haemodialysis, and acute pyelonephritis / perinephric abscess / urosepsis
Key Clinical Precautions: Renal: Excreted 90% unchanged in urine; avoid if CrCl <10 mL/min. Hepatic: Safe (no hepatic metabolism); safe in pregnancy (Category B) for lower UTI!
8. Adverse Effects Profile
- Mild diarrhoea or loose stools (5–10%), nausea, headache, vaginitis
- Rare angioedema, C. difficile colitis, or optic neuritis
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Metoclopramide and other gastroprokinetics accelerate intestinal transit and reduce Fosfomycin absorption and urinary concentration by 25–30% — avoid co-administration!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: HOW TO TAKE MONUROL / FOSFOCIN SACHET: (1) Wait 2 hours after dinner; (2) Empty your bladder completely right before bed; (3) Mix the packet in half a glass of cool/room-temperature water (never hot water) and drink immediately; (4) Because the medicine stays in your bladder for 3 full days, burning will improve over 48 hours
- Meal & Clock Timing Instruction: MANDATORY BEDTIME ADMINISTRATION RULE: Dissolve the 3 g sachet in half a glass (100–120 mL) of cool water (NEVER hot water!), stir, and drink immediately on an empty stomach (2–3 hours after dinner) AT BEDTIME AFTER EMPTYING THE BLADDER completely! (At Bedtime IMMEDIATELY AFTER Urinating (Single Dose))
- Missed Dose Protocol: Single-dose therapy
- Geriatric Dispensing Pearl: Safe and convenient single-dose option for uncomplicated cystitis in older women
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Granules Sachet: 3 g Fosfomycin (equivalent to 5.631 g Fosfomycin Trometamol)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.26] (p. 105)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.25]-C67 Sulfamethoxazole (Co-trimoxazole 1:5 FDC) — Synergistic Sequential Folate Pathway Inhibitor — DHFR + DHPS Blo
- [8.27]-C68 Teicoplanin — Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICM
- [8.1] Amoxicillin Trihydrate — Aminopenicillin Beta-Lactam Antibiotic (Bactericidal Cell-Wall Pe
- [8.2] Amoxicillin + Clavulanic Acid (Co-amoxiclav) — Aminopenicillin + Irreversible Beta-Lactamase Inhibitor Combinati
